These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 12865931

  • 1. Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines.
    van Geelen CM, de Vries EG, Le TK, van Weeghel RP, de Jong S.
    Br J Cancer; 2003 Jul 21; 89(2):363-73. PubMed ID: 12865931
    [Abstract] [Full Text] [Related]

  • 2. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
    Mitsiades N, Poulaki V, Tseleni-Balafouta S, Koutras DA, Stamenkovic I.
    Cancer Res; 2000 Aug 01; 60(15):4122-9. PubMed ID: 10945619
    [Abstract] [Full Text] [Related]

  • 3. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N, Poulaki V, Mitsiades C, Tsokos M.
    Cancer Res; 2001 Mar 15; 61(6):2704-12. PubMed ID: 11289151
    [Abstract] [Full Text] [Related]

  • 4. Synergistic induction of apoptosis in neuroblastoma cells using a combination of cytostatic drugs with interferon-gamma and TRAIL.
    Johnsen JI, Pettersen I, Ponthan F, Sveinbjørnsson B, Flaegstad T, Kogner P.
    Int J Oncol; 2004 Dec 15; 25(6):1849-57. PubMed ID: 15547726
    [Abstract] [Full Text] [Related]

  • 5. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
    Hesry V, Piquet-Pellorce C, Travert M, Donaghy L, Jégou B, Patard JJ, Guillaudeux T.
    Prostate; 2006 Jun 15; 66(9):987-95. PubMed ID: 16541419
    [Abstract] [Full Text] [Related]

  • 6. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis.
    Lacour S, Hammann A, Wotawa A, Corcos L, Solary E, Dimanche-Boitrel MT.
    Cancer Res; 2001 Feb 15; 61(4):1645-51. PubMed ID: 11245478
    [Abstract] [Full Text] [Related]

  • 7. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs.
    Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC, Krueger A, Weigand MA, Grosse-Wilde A, Stremmel W, Krammer PH, Walczak H.
    Cell Death Differ; 2004 Jul 15; 11 Suppl 1():S86-96. PubMed ID: 15105837
    [Abstract] [Full Text] [Related]

  • 8. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas.
    Koornstra JJ, Kleibeuker JH, van Geelen CM, Rijcken FE, Hollema H, de Vries EG, de Jong S.
    J Pathol; 2003 Jul 15; 200(3):327-35. PubMed ID: 12845629
    [Abstract] [Full Text] [Related]

  • 9. Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy.
    Bouralexis S, Findlay DM, Atkins GJ, Labrinidis A, Hay S, Evdokiou A.
    Br J Cancer; 2003 Jul 07; 89(1):206-14. PubMed ID: 12838325
    [Abstract] [Full Text] [Related]

  • 10. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
    Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN.
    Cancer Res; 2001 Jan 15; 61(2):759-63. PubMed ID: 11212279
    [Abstract] [Full Text] [Related]

  • 11. Potential mechanism of resistance to TRAIL-induced apoptosis in Burkitt's lymphoma.
    Tafuku S, Matsuda T, Kawakami H, Tomita M, Yagita H, Mori N.
    Eur J Haematol; 2006 Jan 15; 76(1):64-74. PubMed ID: 16343273
    [Abstract] [Full Text] [Related]

  • 12. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells.
    Delmas D, Rébé C, Micheau O, Athias A, Gambert P, Grazide S, Laurent G, Latruffe N, Solary E.
    Oncogene; 2004 Nov 25; 23(55):8979-86. PubMed ID: 15480430
    [Abstract] [Full Text] [Related]

  • 13. Identification of interleukin 8 as an inhibitor of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in the ovarian carcinoma cell line OVCAR3.
    Abdollahi T, Robertson NM, Abdollahi A, Litwack G.
    Cancer Res; 2003 Aug 01; 63(15):4521-6. PubMed ID: 12907626
    [Abstract] [Full Text] [Related]

  • 14. Sensitivity of Ewing's sarcoma to TRAIL-induced apoptosis.
    Kontny HU, Hämmerle K, Klein R, Shayan P, Mackall CL, Niemeyer CM.
    Cell Death Differ; 2001 May 01; 8(5):506-14. PubMed ID: 11423911
    [Abstract] [Full Text] [Related]

  • 15. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer.
    Mori T, Doi R, Toyoda E, Koizumi M, Ito D, Kami K, Kida A, Masui T, Kawaguchi Y, Fujimoto K.
    Surgery; 2005 Jul 01; 138(1):71-7. PubMed ID: 16003319
    [Abstract] [Full Text] [Related]

  • 16. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release.
    Röhn TA, Wagenknecht B, Roth W, Naumann U, Gulbins E, Krammer PH, Walczak H, Weller M.
    Oncogene; 2001 Jul 12; 20(31):4128-37. PubMed ID: 11464279
    [Abstract] [Full Text] [Related]

  • 17. Expression of TNF-related apoptosis-inducing ligand (TRAIL) and its receptors in gastric carcinoma and tumor-infiltrating lymphocytes: a possible mechanism of immune evasion of the tumor.
    Koyama S, Koike N, Adachi S.
    J Cancer Res Clin Oncol; 2002 Feb 12; 128(2):73-9. PubMed ID: 11862476
    [Abstract] [Full Text] [Related]

  • 18. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
    Hotta T, Suzuki H, Nagai S, Yamamoto K, Imakiire A, Takada E, Itoh M, Mizuguchi J.
    J Orthop Res; 2003 Sep 12; 21(5):949-57. PubMed ID: 12919886
    [Abstract] [Full Text] [Related]

  • 19. Synergistic antitumor activity of TRAIL combined with chemotherapeutic agents in A549 cell lines in vitro and in vivo.
    Fan QL, Zou WY, Song LH, Wei W.
    Cancer Chemother Pharmacol; 2005 Feb 12; 55(2):189-96. PubMed ID: 15290100
    [Abstract] [Full Text] [Related]

  • 20. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo.
    Singh TR, Shankar S, Chen X, Asim M, Srivastava RK.
    Cancer Res; 2003 Sep 01; 63(17):5390-400. PubMed ID: 14500373
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.